Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025HematologyOpen Access

Retrospective analysis of ruxolitinib as induction treatment in pediatric hemophagocytic lymphohistiocytosis

View Full Paper
Ask AI
Bookmark
Share

Authors

SGShu-yi GuoSun Yat-sen UniversityJHJunyan HanCapital Medical UniversityKQKun‐yin QiuSun Yat-sen University

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows improved survival in pediatric patients with hemophagocytic syndrome, indicating efficacy of ruxolitinib with or without chemotherapy.

Key Points

  • Ruxolitinib treatment resulted in an overall survival rate of 78.3% at two years, highlighting its effectiveness.
  • Response rates at weeks 2, 4, and 8 were 73.5%, 76.4%, and 70.6%, indicating notable efficacy over time.
  • Analysis based on retrospective data included 34 pediatric patients diagnosed with hemophagocytic lymphohistiocytosis.
  • Initial treatment response to ruxolitinib was linked to better prognostic outcomes, suggesting its importance in analysis.

Cite This Study

Guo et al. (2025) studied this question.

synapsesocial.com/papers/68c1b80c54b1d3bfb60ebb5bhttps://doi.org/10.1080/16078454.2025.2526124
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Accelerated response and reduced chemotherapy with ruxolitinib-based regimen therapy in pediatric hemophagocytic lymphohistiocytosis: a retrospective comparison with HLH-94 regimen2026 · 1 citations
  2. 2Nationwide survey of ruxolitinib administration for Japanese children with hemophagocytic lymphohistiocytosis2026
  3. 3HLHRUXO: A prospective trial of a ruxolitinib-containing regimen for children with hemophagocytic lymphohistiocytosis2026
  4. 4Differential efficacy and safety of ruxolitinib in primary versus secondary hemophagocytic lymphohistiocytosis: a systematic review and meta-analysis2026
  5. 5Ruxolitinib in malignancy-associated hemophagocytic lymphohistiocytosis (M-HLH): A systematic literature review2025